Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Differentiated approach and indications for optimization of agomelatine therapy for endogenous depression

https://doi.org/10.14412/2074-2711-2019-2-71-77

Full Text:

Abstract

Objective: to develop and justify differentiated indications for the use of agomelatine (valdoxan) to treat the typological variants of endogenous depressions with varying severity on the basis of an analysis of its therapeutic efficacy.

Patients and methods. An open prospective study was conducted using the clinical, psychopathological, and psychometric rating scales: the Hamilton Depression Rating Scale (HAMD-21); Udvalg for Kliniske Undersњgelser Scale (UKU); the Snaith-Hamilton Pleasure Scale (SHAPS) for assessing anhedonic disorders, and statistical methods. Examinations were made in 56 patients (mean age, 34.9 years) with moderate and severe endogenous depression within affective psychosis (n=42) and shift-like schizophrenia (n=14) (ICD-10 items F31.3–4; F32.1–2, and F33.1–2). The patients received a cycle treatment with agomelatine (valdoxan) 25–50 mg once a day in the evening for 4–8 weeks. The patients' status was evaluated over time on fixed days from a reduction in the mean total score (MTS) of the respective scales as insignificant (less than 19% reduction in disorders), moderate (20–49%), good (50–69%), and excellent (70% or more) effects. The effect of agomelatine was analyzed in two patient groups. The specific features of the antidepressive effect and its dynamics in the presence of endogenous depressions of different typologies (melancholic, anxious, and adynamic depressions) were studied in Group 1 (n=26); the effect of agomelatine on anhedonic endogenous depressions and manifestations of anhedonia in different mental activity areas (interests, social activity, emotional engagement and eating/drinking) was investigated in Group 2 (n=30).

Results and discussion. There was a good tolerance and a high antidepressant activity of agomelatine during its treatment cycle for moderate and severe endogenous depressions. A significant improvement (an 84.4% reduction in HAMD-21 MTS) was noted in patients at 3 and 4 weeks of the treatment cycle and consistently persisted at a subsequent follow-up. Agomelatine showed a good effect (a 50% or more reduction in HAMD-21 MTS) just at 14 days of therapy. The drug was observed to have a balanced antidepressant effect, significant thymoleptic, stimulant, anxiolytic, and antianhedonic activities (reductions in the MTS of depressive disorders by 90.83, 84.9, 82.39, and 78.9%, respectively).

Conclusion. The universal spectrum of the antidepressive effect of agomelatine, its good tolerability, high efficacy, and rapid improvement makes it the drug of choice in treating a wide range of psychopathological endogenous depressions: melancholic, apatho-adynamic, anxious, and anhedonic ones.

About the Authors

L. I. Abramova
Mental Health Research Center, Ministry of Science and Higher Education of the Russian Federation
Russian Federation

Lilia Ivanovna Abramova

34, Kashirskoe Shosse, Moscow 115522



G. P. Panteleeva
Mental Health Research Center, Ministry of Science and Higher Education of the Russian Federation
Russian Federation

34, Kashirskoe Shosse, Moscow 115522



I. Yu. Nikiforova
Mental Health Research Center, Ministry of Science and Higher Education of the Russian Federation
Russian Federation

34, Kashirskoe Shosse, Moscow 115522



T. E. Novozhenova
Mental Health Research Center, Ministry of Science and Higher Education of the Russian Federation
Russian Federation

34, Kashirskoe Shosse, Moscow 115522



References

1. Wong ML, Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov. 2004 Feb;3(2):136-51.

2. Srinivasan V, Pandi-Perumal SR, Trakht I, et al. Pathophysiology of depression: role of sleep and the melatonergic system. Psychiatry Res. 2009 Feb 28;165(3):201-14. doi: 10.1016/j.psychres.2007.11.020. Epub 2009 Feb 1.

3. Amon M, Buae PT, Moke E. Prospects in the study of pathogenesis and therapy of affective disorders: the role of melatonin and serotonin. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2007;107(11):77-82. (In Russ.).

4. Racagni G, Riva MA, Popoli M. The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol. 2007 Oct;22 Suppl 2:S9-S14.

5. Hardeland R, Poeggeler B, Srinivasan V, et al. Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008;58(1):1-10. doi: 10.1055/s-0031-1296459.

6. Guilleminault C. Efficacy of the new antidepressant agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder. Eur. Neuropsychopharmacol. 2005; 15(Suppl 3):419.

7. Kennedy SH, Rizvi S, Fulton K, et al. A double-blind comparison of sexual functioning, antidepressant efficacy and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 2008 Jun;28(3):329-33. doi: 10.1097/JCP.0b013e318172b48c.

8. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol. 2007 Sep;22(5):283-91.

9. Hasler BP, Buysse DJ, Kupfer DJ, Germain A. Phase relationships between core body temperature, melatonin, and sleep are associated with depression severity: further evidence for circadian misalign mention-seasonal depression. Psychiatry Res. 2010 Jun 30;178(1): 205-7. doi: 10.1016/j.psychres.2010.04.027. Epub 2010 May 14.

10. Di Giannantonio M, Di Iorio G, Guglielmo R, et al. Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents. 2011 Jan-Mar;25(1):109-14.

11. Martinotti G, Sepede G, Gambi F, et al. Agomelatine Versus Venlafaxine XR in the Treatment of Anhedonia in Major Depressive Disorder. A Pilot Study. J Clin Psychopharmacol. 2012 Aug;32(4):487-91. doi: 10.1097/JCP.0b013e31825d6c25.

12. Medvedev VE, Gushanskaya EV, Israelyan AYu. Therapy of depression with symptoms of anhedonia (experience of valdoxan). Psikhiatriya i psikhofarmakoterapiya im. P.B. Gannushkina. 2014;16(3):45-9. (In Russ.)

13. Petrova NN. On the treatment of depression in patients with schizophrenia. Psikhiatriya i psikhofarmakoterapiya im. P.B. Gannushkina. 2014;16(2):25-8. (In Russ.).

14. Sorokin SA. Endogenous apathetic depression (questions of psychopathology, clinics and therapy). Autoref. diss. cand. med. sci. Moscow; 2015. 24 p.


For citation:


Abramova L.I., Panteleeva G.P., Nikiforova I.Y., Novozhenova T.E. Differentiated approach and indications for optimization of agomelatine therapy for endogenous depression. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(2):71-77. (In Russ.) https://doi.org/10.14412/2074-2711-2019-2-71-77

Views: 28


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)